Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 04, 2021

18F-Fluorodeoxyglucose PET or 18F-Fluorothymidine PET to Assess Early Response to Aromatase Inhibitors in Women With ER+ Operable Breast Cancer

Breast Cancer Research


Additional Info

Breast Cancer Research
18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study
Breast Cancer Res 2021 Aug 23;23(1)88, PE Romine, LM Peterson, BF Kurland, DW Byrd, A Novakova-Jiresova, M Muzi, JM Specht, RK Doot, JM Link, KA Krohn, PE Kinahan, DA Mankoff, HM Linden

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading